| 摘要 |
An isolated polynucleotide (I) comprising a 1873 base pair sequence (S1), given in the specification, provided that the sequence comprises at least one single nucleotide polymorphisms (SNP) selected from g771c, 808Ins(a), and a sequence complementary to S1, is new. Independent claims are also included for the following: (1) an isolated polynucleotide (II) that codes for a polypeptide comprising a sequence (S2) of 187 or 57 amino acids fully defined in the specification, and having the coding SNP G45R; (2) genotyping (M1) a polynucleotide having 80-100 % identity with S1, by amplifying a region of interest in the genomic DNA of a subject or a population of subjects, and determining the allele of at least one position in S1 chosen from 771 or 808; (3) a recombinant vector (III) comprising (I); (4) a host cell (IV) comprising (III); (5) a polypeptide (V) encoded by (I); (6) an immunospecific antibody (VI) obtained using (V); (7) a therapeutic agent (VII) comprising (I), (III), (IV), (V), or (VI) that is specific for any one of S2 of (V); (8) determining (M2) statistically relevant associations between at least one single nucleotide polymorphism (SNP) selected from g771c, 808Ins(a), in the interferon (IFN) alpha -17 gene, and a disease or resistance to disease, by genotyping a group of individuals, determining the distribution of the disease or resistance to the disease within the group of individuals, comparing the genotype data with the distribution of the disease or resistance to disease; and analyzing the comparison for statistically relevant associations; (9) diagnosing or determining (M3) a prognosis of a disease or a resistance to a disease, by detecting at least one SNP selected from g771c, and 808Ins(a), in the IFN alpha -17 gene; (10) identifying (M4) a compound among one or more compounds to be tested having a biological activity similar to the activity of G45R mutated IFN alpha -17 gene product, comprising: (a) determining the biological activity of the compound, such as dendritic cell maturation, cytokine release by CD4<+> or CD8<+> T-lymphocytes, cytokine release by monocytes, cellular antiproliferative activity on TF-1 cell line, cellular antiproliferative activity on Daudi Burkitt's cell line, in vitro or in vivo antiviral activity; (b) comparing the activity of the compound determined with the activity of the G45R mutated IFN alpha -17 gene product; and (c) determining, on the basis of the comparison, whether the compound has a substantially similar, or lower, or higher, activity compared to that of the G45R mutated IFN alpha -17 gene product; and (11) a compound (VIII) identified by M4.
|
